We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc. (NASDAQ:GILD)'s share was trading at $91.41 as of Jan 3rd. GILD’s forward P/E was 12.11 according to Yahoo Finance.
[caption id="attachment_564049" align="aligncenter" width="750"]Gilead Sciences (NASDAQ:GILD) is positioned for significant growth, driven by its breakthrough HIV prevention drug, Lenacapavir, and advancements in its hepatitis and oncology...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.